Jun. 29, 2011
MediciNova of San Diego has formed a JV with Zhejiang Medicine and a Beijing company. Announced on June 30, 2011, the JV is to receive the China rights to develop and commercialize MediciNova’s asthma drug, the MN-221. Zhejiang Medicine has invested RMB 5.7 million for a 40% share of the JV.
Zhejiang Medicine expects to file an IND with the SFDA for the drug by year-end.